Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Cassava Sciences announces phase IIa data for PTI-125 in Alzheimer's disease

Sep. 10, 2019

Results from phase II ADAMANT trial of AADvac-1 in Alzheimer's disease reported

Sep. 10, 2019

Phospholipase D inhibitors developed for testing in neurodegeneration models

Sep. 10, 2019

Experimental model developed for PACAP-induced headache

Sep. 10, 2019

Cheerful gut bug has relationship with antidepressant

Sep. 10, 2019

Passage Bio licenses gene therapy program for CMT2A from Penn

Sep. 9, 2019

Acadia's phase III study of pimavanserin in dementia-related psychosis meets primary endpoint

Sep. 9, 2019

Boehringer Ingelheim, Hydra Biosciences patent TRPC6 antagonists

Sep. 9, 2019

CAD-1883 demonstrates promising safety in phase I study

Sep. 6, 2019

An organoid model for prenatal brain development

Sep. 6, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...